Therapy News and Research

RSS

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.

26 Mar 2010

Survival improving in patients with HER2 positive metastatic breast cancer

Barcelona, Spain: Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Anxiety may rise again, says Rutgers University dean

Poet W.H Auden dubbed the post-World War II nuclear era the "age of anxiety" and indeed, at the time, anxiety disorders were the most commonly diagnosed mental illnesses. Yet, by the 1990s, American psychiatry was "Listening to Prozac" and instead of obsessing about angst, it focused its attention on depression.

26 Mar 2010

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.

26 Mar 2010

Study finds 15-year outcomes of BCT and mastectomy similar

Two studies to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday) and tomorrow (Saturday), shed light on the treatment options facing women carrying the BRCA1 and BRCA2 genetic mutations which predispose them to breast cancer.

26 Mar 2010

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Medtronic, Inc. today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement comes as the World Congress for Neurorehabilitation is taking place in Vienna, Austria.

26 Mar 2010

Survival rate is improving in HER2 positive breast cancer patients

Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today (Friday 26 March) at the seventh European Breast Cancer Conference.

26 Mar 2010

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today (Friday).

26 Mar 2010

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.

26 Mar 2010

Global home health management market expanding at CAGR of 10% through 2012

Remote health management is the fastest growing segment of a burgeoning home health management market. However, RHM’s full potential will materialize only if health insurers adopt reimbursement practices that encourage greater physician adoption, concludes Scientia Advisors, a global strategy consulting firm, in its review of the worldwide home health management market released today.

26 Mar 2010

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Recurrence of breast cancer in the same area as the original tumour remains the strongest, independent prognostic factor for subsequent metastasis and death, even for patients who have been free of disease for a very long time, according to research presented today (Wednesday) at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population.

26 Mar 2010

Medical conditions put seniors at high risk of unsubsidized medical prescription expenses

If you're older, a woman, and suffering from either dementia or diabetes, you are the most likely to be exposed to unsubsidized medication costs in the US. This is known as the coverage gap for enrollees of Medicare Part D - the US federal program which subsidizes the cost of prescription drugs for Medicare beneficiaries.

26 Mar 2010

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Two key, independent proof-of-concept studies conducted for NellOne Therapeutics, Inc. demonstrate the potential efficacy of the company’s lead therapeutic candidate for both skeletal muscle wound healing and myocardial infarction.

26 Mar 2010

Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment

Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors, prescribed drugs that inhibit the effect of an important enzyme.

26 Mar 2010

Pregnancy safe for breast cancer survivors, says study

Women who have been treated for breast cancer can choose to become pregnant and have babies, without fears that pregnancy could put them at higher risk of dying from their cancer, according to a major, new study.

26 Mar 2010

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

$UCSF study: Unusual femur fractures low in patients with osteoporosis$

UCSF study: Unusual femur fractures low in patients with osteoporosis

The occurrence of an unusual type of fracture of the femur, or the thigh bone, is very low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according to a new study led by a team of UCSF epidemiologists.

26 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

Therapy News and Research

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

Survival improving in patients with HER2 positive metastatic breast cancer

Anxiety may rise again, says Rutgers University dean

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Study finds 15-year outcomes of BCT and mastectomy similar

Presence of protein PARP in tumours may help predict response to chemotherapy

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Survival rate is improving in HER2 positive breast cancer patients

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Global home health management market expanding at CAGR of 10% through 2012

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

Medical conditions put seniors at high risk of unsubsidized medical prescription expenses

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment

Pregnancy safe for breast cancer survivors, says study

NYU researchers identify novel therapy for rheumatoid arthritis

UCSF study: Unusual femur fractures low in patients with osteoporosis

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News